Physician profile
John D Rowe
NPI 1891815924
$529.97
in general payments reported to CMS, 2019-2025
15 companies · $158 in 2025
The $158 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $118 · 2022: $74.12 · 2023: $95.29 · 2024: $83.99 · 2025: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $337.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $95.90 | 2022-2025 | |
| Exact Sciences Corporation | $63.56 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Xeris Pharmaceuticals, INC. | $52.60 | 2025 | Gvoke Hypopen, Keveyis |
| Pfizer INC. | $47.84 | 2021 | |
| Merck Sharp & Dohme LLC | $42.05 | 2021 | |
| Axsome Therapeutics, INC. | $33.79 | 2024 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.54 | 2023 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $29.77 | 2024-2025 | Airsupra, Breztri |
| Sumitomo Pharma America, INC. | $25.43 | 2023 | Aptiom |
| Novo Nordisk INC | $22.03 | 2025 | Wegovy |
| Sunovion Pharmaceuticals INC. | $20.71 | 2022 | |
| Abbott Laboratories | $19.08 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.05 | 2021 | |
| Lilly USA, LLC | $15.33 | 2025 | Zepbound, Mounjaro |
| Kowa Pharmaceuticals America, INC. | $11.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Rowe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.